Lucid Diagnostics Insider Ups Holding By 162% During Year [Yahoo! Finance]
Facing a higher risk of cancer, New Castle firefighters increase efforts for early detection [CBS News]
Here's Why Lucid Diagnostics (LUCD) Declined in Q3 [Yahoo! Finance]
Lucid Diagnostics (NASDAQ:LUCD) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $8.25. They now have a "buy" rating on the stock.
Lucid Diagnostics (NASDAQ:LUCD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.